Skip to main content
. 2023 Feb 16;15(2):669. doi: 10.3390/pharmaceutics15020669

Figure 1.

Figure 1

1,2,3,4-Tetrahydroacridine derivatives indicated by the computational studies as promising antileishmanial agents.